154229-18-2 | Abiraterone Acetate

Packsize	Purity	Availability	Price	Discounted Price
25mg	95%	in stock	$63.00	$45.00
100mg	95%	in stock	$153.00	$107.00
1g	95%	in stock	$222.00	$155.00
5g	95%	in stock	$686.00	$480.00
10g	95%	in stock	$1,250.00	$875.00

Description

• Catalog Number: AB47636
• Chemical Name: Abiraterone Acetate
• CAS Number: 154229-18-2
• Molecular Formula: C26H33NO2
• Molecular Weight: 391.54572
• MDL Number: MFCD00934213
• SMILES: CC(=O)O[C@H]1CC[C@]2(C(=CC[C@@H]3[C@@H]2CC[C@]2([C@H]3CC=C2c2cccnc2)C)C1)C

Computed Properties

• Complexity: 739
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 6
• Heavy Atom Count: 29
• Hydrogen Bond Acceptor Count: 3
• Rotatable Bond Count: 3
• XLogP3: 5.2

Literature

• Differential response to abiraterone acetate and di-n-butyl phthalate in an androgen-sensitive human fetal testis xenograft bioassay.

  Toxicological sciences : an official journal of the Society of Toxicology 20140301

• Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC).

  BMC urology 20140101

• Urologists and oncologists: adapting to a new treatment paradigm in castration-resistant prostate cancer (CRPC).

  BJU international 20120801

• Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer.

  Cancer chemotherapy and pharmacology 20120801

• Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120701

• Discovery of potent and orally bioavailable 17β-hydroxysteroid dehydrogenase type 3 inhibitors.

  Bioorganic & medicinal chemistry 20120515

• Novel molecular targets for the therapy of castration-resistant prostate cancer.

  European urology 20120501

• Beyond castration-defining future directions in the hormonal treatment of prostate cancer.

  Hormones & cancer 20120401

• Abiraterone acetate: redefining hormone treatment for advanced prostate cancer.

  Drug discovery today 20120301

• Advances in the management of high-risk localised and metastatic prostate cancer.

  BJU international 20120301

• Abiraterone acetate: a guide to its use in metastatic castration-resistant prostate cancer.

  Drugs & aging 20120301

• The 5α-androstanedione pathway to dihydrotestosterone in castration-resistant prostate cancer.

  Journal of investigative medicine : the official publication of the American Federation for Clinical Research 20120201

• Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor.

  Clinical pharmacology and therapeutics 20120101

• Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer.

  Expert review of anticancer therapy 20120101

• Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.

  Drug design, development and therapy 20120101

• Optimizing outcomes of advanced prostate cancer: drug sequencing and novel therapeutic approaches.

  Oncology (Williston Park, N.Y.) 20120101

• Successful Treatment of Advanced Metastatic Prostate Cancer following Chemotherapy Based on Molecular Profiling.

  Case reports in oncology 20120101

• Drugs in traffic: the road to approval.

  Nature medicine 20111206

• TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate.

  European urology 20111101

• Circulating tumour cells as surrogate biomarkers in castration-resistant prostate cancer trials.

  European urology 20111101

• Clinical implications of the 5α-androstanedione pathway for castration-resistant prostate cancer.

  Future oncology (London, England) 20111101

• Abiraterone acetate: in metastatic castration-resistant prostate cancer.

  Drugs 20111022

• Flushing oral oncology drugs down the toilet.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20111020

• Abiraterone acetate for prostate cancer: a new era of hormonal therapies.

  Asian journal of andrology 20110901

• Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110715

• [The trend toward development of novel agents based on the mechanism of prostate cancer progression].

  Nihon rinsho. Japanese journal of clinical medicine 20110601

• CYP17 inhibitors for prostate cancer therapy.

  The Journal of steroid biochemistry and molecular biology 20110501

• Roflumilast, indacaterol maleate, and abiraterone acetate.

  Journal of the American Pharmacists Association : JAPhA 20110101

• Abiraterone acetate.

  Drugs in R&D 20101101

• CYP17 inhibition as a hormonal strategy for prostate cancer.

  Nature clinical practice. Urology 20081101

• Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17)--part II: Core rigidification and influence of substituents at the methylene bridge.

  Bioorganic & medicinal chemistry 20080815

• Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure.

  Bioorganic & medicinal chemistry 20080215

• Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer.

  British journal of cancer 20040614

• Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer.

  Journal of medicinal chemistry 19950623